PT ENSEVAL PUTERA MEGATRADING Tbk COMPANY UPDATE · PT ENSEVAL PUTERA MEGATRADING Tbk COMPANY...
Transcript of PT ENSEVAL PUTERA MEGATRADING Tbk COMPANY UPDATE · PT ENSEVAL PUTERA MEGATRADING Tbk COMPANY...
Table of Contents
• Enseval In BriefSection
I
• Business Overview Section
II
• Operational HighlightsSection
III
• Financial HighlightsSection
IV
Milestones
Responding to the government regulation which require separation between role of distribution and role of marketing / manufacturing, PT Enseval was established in October 1973
In 1993, PT Enseval transferred all trading and distribution businesses to PT AryaGupta Cempaka, a wholly owned subsidiary, which later change its company name to PT Enseval Putera Megatrading
On 1 August 1994, the Company was listed on Indonesian Stock Exchange
Milestones
1994PT Enseval PuteraMegatrading Tbk conducted its Initial Public Offering
Incorporation of PT Renalmed Tiara Utama in July
PT Enseval Medika Prima, PT Global ChemindoMegatrading & PT Renalmed Tiara Utamastarted operations in October
20082007 Incorporation of Subsidiary : PT Enseval Medika Prima & PT Global ChemindoMegatrading
2003Incorporation of Subsidiary PT MileniaDharma Insani
Company Structures PT Enseval Putera Megatrading Tbk
PT Enseval PuteraMegatrading
Tbk
PT Tri Sapta Jaya
99.9%
PT Milenia Dharma Insani
100.0%
PT Enseval MedikaPrima
100.0%
PT Global ChemindoMegatrading
100.0%
PT Renalmed Tiara Utama
97.5%
Distribution & LogisticProduct Range : Ethical, OTC, Consumer Products, Medical Device &
Raw Material
Our service :
Warehousing
Inventory Management
Freight & Transportation
Sales & Support
Order-taking, Billing & Collection
Distribution & Logistic
Directly and Indirectly covers more than 1,000,000 outlets
Direct delivery to end customers
Cover most pharmacies & hospital
Cover 80% of consumer & health market
24 hour order fulfillment & 4-5 hour order fulfillment for prescription pharma
24 hour service for life saving drug
Offers value added services to customers :
- resource management, strategic sourcing & supply
- needs-basis marketing service
Medical DeviceProduct Range : Consumables, Instruments, Laboratories & Diagnostics, and
Products related to Laboratories Industry
The Company offers Marketing services for medical devices through its subsidiary, PT Enseval Medika Prima and Hemodialysis Treatment in collaboration with clinics and hospitals through PT Renalmed Tiara Utama.
The company has retained the trust & maintained good relationships with multi-national principals
Raw Material
Related to : Pharmaceutical Product, Food, Cosmetics & Veterinary
PT Global Chemindo Megatrading offers trading & marketing ofraw material and has extensive network and collaboration withMultinational Companies from different countries, such as : UnitedStates, Europe, China, Japan, Korea and other countries.
Healthcare Services Healthcare Services through Mitrasana Clinics ,with facilities such as:
Clinic, Pharmacy, Laboratory & Mini market, which now also offers Hemodialysis treatment.
Until 30 June 2010, The Company has 20 Clinics in Jakarta and its greater areas
Offered in 2 business models : direct investment & collaboration / joint operation models
Events Highlights
Infrastructures & Branches Development in branches, such as : Bekasi, Pematang Siantar.
The Company awarded as ‘Pharmaceutical distribution Company that has the most outlet’ from Rekor Bisnis Indonesia
The Company conducted its AGMS on May 18, 2010
New Principals In June 2010, PT Perkebunan Nusantara VIII joined as new
principal with its ready to drink tea product ‘ Walini Tea’
Branches The largest pharmaceutical distribution network throughout theIndonesian Archipelago with 42 Branches (EPM), 2 Regional DistributionCenter, Located in Jakarta & Surabaya & 23 Branches under subsidiarycompany (TSJ)
Human Resources Employs over 4,000 personnel with over 2,000 personnel are working in sales and
distribution
The Company continues to provide training for all employees to improved its human resources competencies
In year 2010, The Company continues to promote CONIM Program (ContinuosImprovement) to all staffs, both in Headquarters & in all Branches.
Principals Based on Categories
Medical Devices & Diagnostic Raw Material
Friesland Foods Domo
Major Principals
Infrastructures
Approximately 650 Transportation FleetApproximately 400 Motorcycles
More than 61.000 Pallets Size
The Usage of Oracle System as IT Platform
Financial Highlights
Net Sales Operating Income
Until YTD 30 June 2010, The Company recorded Net Sales of IDR 4.4 trillion, with Operating Income amounting to IDR 99.1 billion
6.4
7.4
8.6
4.4
15.4% 16.1% 15.7%
10.6%
0.0%
2.0%
4.0%
6.0%
8.0%
10.0%
12.0%
14.0%
16.0%
18.0%
0.0
1.0
2.0
3.0
4.0
5.0
6.0
7.0
8.0
9.0
10.0
2007 2008 2009 H1 2010
NS ( IDR Trillion) Growth
307
363
484
143
4.8%4.9%
5.7%
3.2%
0.0%
1.0%
2.0%
3.0%
4.0%
5.0%
6.0%
0
100
200
300
400
500
600
2007 2008 2009 H1 2010
Operating Profit (IDR Billion) Operating Profit Margin
Financial Highlights
231
267
329
99
3.6%
3.6%3.9%
2.2%
0.0%
0.5%
1.0%
1.5%
2.0%
2.5%
3.0%
3.5%
4.0%
4.5%
0
50
100
150
200
250
300
350
2007 2008 2009 YTD 30 June 10
Net Income (IDR Million) Net Profit Margin
Net Income
102
117
144
63
0
20
40
60
80
100
120
140
160
2007 2008 2009 YTD 30 June 10
Net Income Per Share (IDR)
Net Income Per Share
Until YTD 30 June 2010, The Company Net Income was IDR 99.1 million , decline 32.9% YoY with Net Income Per Share of IDR 63
1,444
1,162
774
325 266
16
1,671
1,386
776
355
209
14
Consumer Products Ethical OTC Raw Material Medical Device Others
YTD 30 June 09 YTD 30 June 10 (IDR Billion)
9.2%
13.2%
0.3%
19.2%
15.7%
21.3%
Net Sales By Division
Sales Contribution
72%
28%
74%
26%
Kalbe Grup
3rd Party
YTD 30 June 2010 YTD 30 June 2009
Until YTD 30 June 10 Kalbe Group’s Sales contributes % of total sales, while the remaining % are from 3rd party Principals.
Consumer Products
37%
Ethical 31%
OTC 18%
Medical Device
5%
Raw Material 8%
Others0%
Sales Contribution
Consumer Products
36%
Ethical 29%
OTC20%
Medical Device
7%
Raw Material 8%
Others0%
YTD 30 June 2010
YTD 30 June 2009
2,518
378
2,896 3,045
429
3,474
Current Assets Non Current Assets
Total Assets
30 June 09 (IDR Billion)
30 June 10 (IDR Billion)
21.0%
13.6%
20.0%
Assets
1,438
35
1,473
1,752
82
1,833
Current Liablities Non Current Liabilities Total Liabilities
30 June09 (IDR Billion) 30 June 10(IDR Billion)
Liabilities & Equity
1,422
1,640
Equity
30 June 09 (IDR Billion) 30 June 10 (IDR Billion)
24.5%
15.3%
132.7%
21.8%
Thank You For further information, please contact :
PT Enseval Putera Megatrading Tbk.
Enseval Building, Kawasan Industri Pulogadung
Jalan Pulolentut No.10
Jakarta 13920 – Indonesia
Phone : 62-21-46822422 Fax : 62-21-4609039
Website : www.enseval.com
Email : [email protected]
IMPORTANT NOTICE
This presentation has been prepared for informational purposes only by PT Enseval Putera
Megatrading Tbk. (“Enseval” or the “Company”).
The information contained in this Presentation does not purport to be all-inclusive or to
contain all of the information that may be material to an investor’s decision. It should be
noted that the information contained in this Presentation is subjected to further review, and
that such information may be updated and/or amended from time to time as
circumstances change or more information becomes available. Some of those revisions or
changes may be material.
Each recipient of this Presentation should therefore perform their own independent
analysis of the business, operations, financial condition, creditworthiness, status and
affairs of Enseval. Each recipient should also conduct their own enquiries into the
adequacy, accuracy, and completeness of any information relating to Enseval, as the
information and data contained in this Presentation are not substitutes for the recipient’s
independent evaluation and analysis.
This presentation is not an offering document and will be updated regularly as necessary.